Evidence map›Paper›PMID 35781320›Full record

ArticleRheumatology (Oxford, England)2023

Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis.

Tomohiro Koga, Masataka Umeda, Nobuya Yoshida, Abhigyan Satyam, Meenakshi Jha, Marc Scherlinger, Rhea Bhargava, Maria G Tsokos, Tomohito Sato, Kaori Furukawa and 8 more

Open access · greenAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Tomohiro KogaDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
Masataka UmedaDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
Nobuya YoshidaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Abhigyan SatyamDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Meenakshi JhaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Marc ScherlingerDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9453-5895
Rhea BhargavaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Maria G TsokosDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Tomohito SatoDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
Kaori FurukawaDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
Yushiro EndoDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
Shoichi FukuiDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
Naoki IwamotoDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.ORCID 0000-0002-2197-0757
Norio AbiruDepartment of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences.
Minoru OkitaDepartment of Physical Therapy Science, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki.
Masako ItoNagasaki Study Center, The Open University of Japan, Chiba, Japan.
Atsushi KawakamiDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences.
George C TsokosDivision of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9589-2360
Beth Israel Deaconess Medical Center · USNagasaki University · JPThe Open University of Japan · JP

Funding

LYMPHOCYTE SIGNALING DEFECTS IN PATIENTS WITH LUPUSR01AI042269 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI TSOKOS, GEORGE C · 1998 to 2017
$6.8M
T cells in LupusR01AI148161 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TSOKOS, GEORGE C · 2020 to 2024
$2.2M
NIAID NIH HHS R01 AI042269NIAID NIH HHS R01 AI148161
6 · The paper itself

Abstract

objectiveTo investigate the role of calcium/calmodulin-dependent protein kinase IV (CaMK4) in the development of joint injury in a mouse model of arthritis and patients with RA.

methodsCamk4-deficient, Camk4flox/floxLck-Cre, and mice treated with CaMK4 inhibitor KN-93 or KN-93 encapsulated in nanoparticles tagged with CD4 or CD8 antibodies were subjected to collagen-induced arthritis (CIA). Inflammatory cytokine levels, humoral immune response, synovitis, and T-cell activation were recorded. CAMK4 gene expression was measured in CD4+ T cells from healthy participants and patients with active RA. Micro-CT and histology were used to assess joint pathology. CD4+ and CD14+ cells in patients with RA were subjected to Th17 or osteoclast differentiation, respectively.

resultsCaMK4-deficient mice subjected to CIA displayed improved clinical scores and decreased numbers of Th17 cells. KN-93 treatment significantly reduced joint destruction by decreasing the production of inflammatory cytokines. Furthermore, Camk4flox/floxLck-Cre mice and mice treated with KN93-loaded CD4 antibody-tagged nanoparticles developed fewer Th17 cells and less severe arthritis. CaMK4 inhibition mitigated IL-17 production by CD4+ cells in patients with RA. The number of in vitro differentiated osteoclasts from CD14+ cells in patients with RA was significantly decreased with CaMK4 inhibitors.

conclusionUsing global and CD4-cell-targeted pharmacologic approaches and conditionally deficient mice, we demonstrate that CaMK4 is important in the development of arthritis. Using ex vivo cell cultures from patients with RA, CaMK4 is important for both Th17 generation and osteoclastogenesis. We propose that CaMK4 inhibition represents a new approach to control the development of arthritis.

Indexed as

Arthritis, ExperimentalOsteogenesisAnimalsBenzenesulfonamidesBenzylaminesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 4Cell DifferentiationCytokinesMiceTh17 CellsBenzenesulfonamidesBenzylaminesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 4CytokinesKN 93bone destructionCaMK4IL-17RAT cells

Identifiers

PMID35781320
PMCPMC9891404
OpenAlexW4283791187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.